REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer.

[1]  E. Cicinelli,et al.  Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer , 2017, International journal of molecular sciences.

[2]  M. Stockler,et al.  Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  C. Tempfer,et al.  Nutritional status, cachexia, and anorexia in women with peritoneal metastasis and intraperitoneal chemotherapy: a longitudinal analysis , 2017, Journal of gynecologic oncology.

[4]  V. Rudralingam,et al.  Ascites matters , 2017, Ultrasound.

[5]  G. Mills,et al.  The management of malignant ascites and impact on quality of life outcomes in women with ovarian cancer , 2016, Expert review of quality of life in cancer care.

[6]  B. Monk,et al.  Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study. , 2015, Gynecologic oncology.

[7]  Jianhua Cai,et al.  Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial , 2015, Medical Oncology.

[8]  M. Stockler,et al.  Development of the Measure of Ovarian Symptoms and Treatment Concerns: Aiming for Optimal Measurement of Patient-Reported Symptom Benefit With Chemotherapy for Symptomatic Ovarian Cancer , 2014, International Journal of Gynecologic Cancer.

[9]  A. Reuss,et al.  Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  T. Miner,et al.  Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures. , 2012, World journal of gastrointestinal surgery.

[11]  Jacobus Pfisterer,et al.  A phase 3 trial of bevacizumab in ovarian cancer. , 2011, The New England journal of medicine.

[12]  B. Monk,et al.  Incorporation of bevacizumab in the primary treatment of ovarian cancer. , 2011, The New England journal of medicine.

[13]  J. Yi,et al.  OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  I. Ruscito,et al.  Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review , 2010, Investigational New Drugs.

[15]  M. Spasojevic,et al.  Intra-abdominal administration of bevacizumab diminishes intra-peritoneal adhesions. , 2010, American journal of surgery.

[16]  P. Murawa,et al.  The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial , 2010, International journal of cancer.

[17]  R. Barakat,et al.  Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma. , 2010, Gynecologic oncology.

[18]  C. Bokemeyer,et al.  Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? , 2009, The oncologist.

[19]  Mildred R. Chernofsky,et al.  Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. , 2008, Gynecologic oncology.

[20]  Michael W Sill,et al.  Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Howard Mackey,et al.  Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  K. El-Shami,et al.  Open-label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascites , 2007 .

[23]  C. Lindley,et al.  Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. , 2006, Clinical therapeutics.

[24]  M. Barnes,et al.  The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. , 2006, Gynecologic oncology.

[25]  J. Sehouli,et al.  Accumulation of Selected Carotenoids, α-Tocopherol and Retinol in Human Ovarian Carcinoma Ascitic Fluid , 2004, Annals of Nutrition and Metabolism.

[26]  A. Bottomley,et al.  An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. , 2003, European journal of cancer.

[27]  M. Markman.  Intraperitoneal antineoplastic drug delivery: rationale and results. , 2003, The Lancet. Oncology.

[28]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.